Views & Analysis 5 years of biosimilars in the US: what have we learned? Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide.
Views & Analysis Who could replace Sir Andrew Dillon at NICE? With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health
News Australia first for Hansa’s Idefirix in commercial kidney tr... Hansa has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.